My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Betaxolol HCl (SL75212)
    Betaxolol HCl (SL75212)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1106
    CAS #: 63659-19-8Purity ≥98%

    Description: Betaxolol HCl (Betoptima; Kerlone; Betoptic; Kerlon; SL-75212; ALO-1401-02; ALO140102), the hydrochloride salt of Betaxolol, is a potent beta-1/β1 adrenergic receptor antagonist with antihypertensive effects. It inhibits beta-1/β1 adrenergic receptor with an IC50 of 6 μM. Betaxolol has been approved for the treatment of hypertension and glaucoma.  

    References: Exp Eye Res. 2003 Apr;76(4):505-16; Exp Eye Res. 1999 Sep;69(3):331-42.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)343.89 
    CAS No.63659-19-8 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 69 mg/mL (200.6 mM)
    Water: 69 mg/mL (200.6 mM)
    Ethanol: N/A
    Solubility (In vivo)Saline: 30 mg/mL 
    SynonymsSL-75212 HCl; ALO 140102; SL 75212 HCl; Betaxolol Hydrochloride; Betaxolol HCL; Betoptima; Kerlone; Betoptic; Kerlon; SL75212 HCl; ALO-1401-02; ALO140102

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Betaxolol is able to protect retinal neurons. Betaxolol attenuates the NMDA-induced influx of 45Ca2+ while β-adrenoreceptor agonists are ineffective. The glutamate-induced release of LDH is almost completely prevented when betaxolol (10 μM) is included. Betaxolol (100 μM) is very effective in preventing the hypoxia-induced release of LDH from cortical cultures.

    Cell Assay: Dissociated cortical cells from 16–18-day-old fetal rats are grown, in 35 mm dishes, in DMEM supplemented with L-glutamine (4 mM), glucose (6 g/L), penicillin (100 U/mL), streptomycin (100 μg/mL) and 10% hormonal supplemented medium consisting of transferrin (1 mg/mL), insulin (250 μg/mL) putrescine (600 μM), sodium selenite (0.3 μM), progesterone (0.2 μM) and estradiol (0.1 pM) for 7 days in an atmosphere of 5% CO2/95% O2 at 37 °C. The cultures are then transferred to a culture medium which lacks the hormonal supplemented medium. L-glutamate is added to the medium and incubated for a further 4 hours under normoxic conditions. Betaxolol are added to the cultures at the same time as L-glutamate. In other experiments the cultures are subjected to anoxic conditions, 95% N2/5% CO2, for 5 hours at 37 °C. Betaxolol is added prior to anoxia. Reoxygenation is then achieved by replacing the cells in normoxic conditions (95% O2/5% CO2) for 3 hours. Cellular injury is assessed by measuring lactate dehydrogenase (LDH) release into the cell culture supernatant after hypoxia/reoxygenation or glutamate exposure. LDH activity is assayed spectrophotometrically by following NADH metabolism for 2 minutes at 340 nm.

    In VivoWhen Betaxolol is injected i.p. into the rats before ischaemia and on the days of reperfusion the changes to the calretinin and ChAT immunoreactivities are reduced and the reduction of the b-wave is prevented. Inclusion of betaxolol partially prevents the changes caused by NMDA and lack of oxygen/glucose. 
    Animal modelRat with ischemia model 
    Formulation & DosageDissolved in saline; 2.5 mg/kg; i.p. injection

    Exp Eye Res. 2003 Apr;76(4):505-16; Exp Eye Res. 1999 Sep;69(3):331-42. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Betaxolol HCl
    Effect of betaxolol on the DNA fragmentation of HCE cells. Int J Ophthalmol. 2014; 7(1): 14–21.
    Betaxolol HCl
    Effect of betaxolol on cat corneas in vivo (n=4). Int J Ophthalmol. 2014; 7(1): 14–21.
    Betaxolol HCl
    Effect of betaxolol on the histological structure of CCE cells in vivo. Int J Ophthalmol. 2014; 7(1): 14–21.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?